SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike Ankley who wrote (3360)7/18/1998 5:02:00 AM
From: Mike Ankley   of 5402
 
Green Cross assigned U.S. patent 4,186,253
Perfusate for preserving organ to be transplanted and preserving method
patents.uspto.gov

Green Cross is the parent company of Alpha Therapeutics. Dr. Drees was President/CEO of Alpha Therapeutics for several years, during which time FDA approval to Alpha for U.S. patent 4,252,827 was achieved.

------------------------------------------------------------------------
Abstract
------------------------------------------------------------------------
An organ to be transplanted, such as kidney, can effectively be preserved by perfusion for a considerably long time by the use of a perfusate which is made by mixing a Ringer's solution modified by increasing potassium ion to 8-20 meq/l, a stable perfluorocarbon compound emulsion and albumin, so that the concentration of the perfluorocarbon compound is 7.5 to 12.5% (W/V) and that of albumin is 1-8% (W/V) based on the perfusate.

Cheers

Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News